A “pandemic” is not 10, 20, 40 or 100 cases per month

NYT:

ZMapp, which is actually a cocktail of three different antibodies, is being developed by Mapp Biopharmaceutical, a tiny San Diego company, with funding from the United States and Canadian governments. The doses used to treat the American aid workers were produced in tobacco leaves at a facility in Owensboro, Ky., that is owned by Reynolds American, the tobacco company. That facility has now resumed production, but the federal official said it was expected to produce only about 10 to 20 treatment courses by the end of the year, and the same amount every month going forward.

So the Biomedical Advanced Research and Development Authority, a branch of the Department of Health and Human Services, is considering additional production from Caliber, which is based in Bryan, Tex., and co-operates on projects with Texas A&M University. Caliber also produces proteins, including antibodies, in hydroponically grown tobacco plants but has a larger production capacity than the Kentucky facility.

No official contract has been signed, so plans could still change. But federal officials have visited Caliber regularly. “They are actively engaged, pretty much on a daily basis, working with Caliber and A&M,” Dr. Brett P. Giroir, the chief executive of the Texas A&M Health Science Center, said Wednesday. Executives at Caliber and Mapp declined to comment for this article.

Both Caliber and the Kentucky facility sprang from a project sponsored by the Defense Advanced Research Projects Agency, which was looking for a way to quickly produce vaccines or therapeutic proteins in the event of an emergency like a flu pandemic.

Now these facilities are likely to get their first big test. “It’s not been tested, live-fire,” the federal official said. “And now we’re doing it.” The system involves infecting tobacco with a genetically engineered virus that contains the instructions to make the antibody. “Every time the virus tries to replicate, it spins out a copy of a monoclonal antibody,” said Charles J. Arntzen, a professor at Arizona State University who has long worked on such systems. The leaves are ground up to extract the antibody.

The federal official said that Caliber and other facilities that will be brought on line could produce 40 to 100 treatment courses per month.

So “Caliber and the Kentucky facility sprang from a project sponsored by the Defense Advanced Research Projects Agency, which was looking for a way to quickly produce vaccines or therapeutic proteins in the event of an emergency like a flu pandemic.” So even DARPA is part of the clown carnival now?

What on earth is wrong with these people in government bureaucracies? The goal is a maximum of 100 treatments a month for a virus that has killed as many as 88% of those who get it and has an incubation period as long as 3 weeks? This effort needs a real CEO and a lot of money and manpower — fast. As we said: Manhattan Project at Warp Speed, nothing less will do.

One Response to “A “pandemic” is not 10, 20, 40 or 100 cases per month”

  1. Neil Says:

    DARPA has done their job and more–this is a proof of concept that’s gone into limited-run production. Full commercialization is not their thing.

    For commercial production, somebody has to place an order. Is ZMapp on the Medicare formulary, or that of any major health insurance company?

Leave a Reply